Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Adalimumab Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Adalimumab Products

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and pharmacy coverage for preferred adalimumab products under the Commercial/Exchange pharmacy benefit. It establishes diagnosis-specific initial authorization criteria, continuation requirements, quantity limits, approval durations, and specialty-pharmacy dispensing requirements for members with rheumatoid arthritis and other labeled inflammatory conditions.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyAdalimumab Products
    Policy CodePolicy N/A
    Change TypeFormulary update
    Effective DateJanuary 1, 2027
    Last ReviewSep 9, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through the Commercial/Exchange pharmacy benefit and use a contracted specialty pharmacy.
    SourceLink
    POLICY UPDATE CHANGES

    Effective January 1, 2027, adalimumab-aaty, adalimumab-adaz, and Hadlima are the Plan's preferred adalimumab products, while all other adalimumab products are nonformulary.

    The policy was renamed to Adalimumab Products.

    3Preferred adalimumab products
    24 monthsInitial authorization and reauthorization duration
    90 daysNew-plan member window for documenting current treatment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 monthsRequired conventional-therapy trial for rheumatoid arthritis
    3% BSAPlaque-psoriasis body-surface-area threshold
    Specialty pharmacyRequired dispensing channel

    Diagnosis-Specific Coverage Criteria

    Initial authorization pathways

    For members new to the Plan, or when the diagnosis-specific pathway is used.

    Initial authorization pathway

    • New-plan member pathway: Member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving the requested drug.Coverage effective date ≤90 days

      Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.

    • Diagnosis-specific pathway: Member meets all criteria for the applicable diagnosis.

      See the applicable diagnosis-specific criteria.

    ],
    ref_placeholder_for_schema_fix

    Moderately to severely active rheumatoid arthritis

    Covered for moderately to severely active rheumatoid arthritis when ALL of the following are met.

    Rheumatoid arthritis criteria

    • ALL of the following

      • Conventional therapy

        • Methotrexate trial at a maximally tolerated dose.
        • Leflunomide trial at a maximally tolerated dose.
        • Sulfasalazine trial at a maximally tolerated dose.

    Moderately to severely active polyarticular juvenile idiopathic arthritis

    Covered for moderately to severely active polyarticular juvenile idiopathic arthritis when ALL of the following are met.

    Polyarticular juvenile idiopathic arthritis criteria

    • ALL of the following

      • Conventional therapy

        • Leflunomide trial at a maximally tolerated dose.
        • Methotrexate trial at a maximally tolerated dose.

    Active psoriatic arthritis

    Covered for active psoriatic arthritis when ALL of the following are met.

    Psoriatic arthritis criteria

    • ALL of the following

      • Qualifying manifestations

        • Actively inflamed joints.
        • Dactylitis.
        • Enthesitis.
        • Axial disease.
        • Active skin and/or nail involvement.

    Active ankylosing spondylitis

    Covered for active ankylosing spondylitis when ALL of the following are met.

    Ankylosing spondylitis criteria

    • Diagnosis of active ankylosing spondylitis and a minimum 1-month trial with failure, contraindication, or intolerance to TWO different nonsteroidal anti-inflammatory drugs at maximally tolerated doses.1-month trial; two different NSAIDs

      Examples include ibuprofen and naproxen.

    Moderately to severely active Crohn's disease

    Covered for moderately to severely active Crohn's disease when ALL of the following are met.

    Crohn's disease criteria

    • ALL of the following

      • Treatment pathway

        • Conventional therapy: Trial and failure, contraindication, or intolerance to ONE qualifying conventional therapy.One therapy

          Qualifying therapies are 6-mercaptopurine, azathioprine, corticosteroids such as prednisone, or methotrexate.

        • First-line systemic therapy: Disease severity warrants systemic biologic or targeted synthetic therapy as first-line therapy.

    Moderately to severely active ulcerative colitis

    Covered for moderately to severely active ulcerative colitis when ALL of the following are met.

    Ulcerative colitis criteria

    • ALL of the following

      • Treatment pathway

        • Conventional therapy: Trial and failure, contraindication, or intolerance to ONE qualifying conventional therapy.One therapy

          Qualifying therapies are 6-mercaptopurine, aminosalicylates such as mesalamine, olsalazine, or sulfasalazine, azathioprine, or corticosteroids such as prednisone.

        • First-line systemic therapy: Disease severity warrants systemic biologic or targeted synthetic therapy as first-line therapy.

    Moderate to severe chronic plaque psoriasis

    Covered for moderate to severe chronic plaque psoriasis when ALL of the following are met.

    Plaque psoriasis criteria

    • ALL of the following

      • Disease extent: At least 3% of body surface area is affected or crucial body areas are affected.≥3% BSA or crucial body area
      • Treatment pathway

        • Topical therapy: Minimum 4-week trial with failure, contraindication, or intolerance to ONE qualifying topical therapy.4-week trial; one therapy

          Qualifying therapies are corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, or coal tar.

    Moderate to severe hidradenitis suppurativa

    Covered for moderate to severe hidradenitis suppurativa when the following is met.

    Hidradenitis suppurativa criteria: Diagnosis of moderate to severe hidradenitis suppurativa classified as Hurley stage II or III.Hurley stage II or III

    Non-infectious uveitis

    Covered for non-infectious uveitis when ALL of the following are met.

    Uveitis criteria

    • ALL of the following

      • Uveitis classification

        • Intermediate uveitis.
        • Posterior uveitis.
        • Panuveitis.

    Continuation therapy

    Reauthorization for all diagnoses will be approved when the following is met.

    Continuation criterion: Medical records, such as chart notes, document improvement in the member's condition, evidenced by low disease activity or improvement in signs and symptoms of the condition.Documented improvement

    Applies to all covered diagnoses.

    Coverage and Quantity Coding Details

    Plaque psoriasis body surface area
    Minimum affected areaAt least 3% of body surface area (BSA)
    Alternative criterionCrucial body areas may be affected instead of meeting the 3% BSA threshold
    Examples of crucial body areasHands, feet, face, neck, scalp, genitals/groin, and intertriginous areas
    Starter pack quantity
    Dosage formStarter pack
    Quantity limit1 pack
    Limit periodPer 365 days

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Commercial/Exchange pharmacy benefit coverage of adalimumab products.

    • Applies to the pharmacy benefit; no medical-benefit coverage is identified in this policy.
    Billing Rule

    Contracted Specialty Pharmacy Required

    This medication is designated specialty and must be filled through a contracted specialty pharmacy.

    Clinical Background

    Adalimumab is a tumor necrosis factor (TNF) blocker used to treat moderately to severely active rheumatoid arthritis and other inflammatory conditions, including polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis.

    Condition Definitions

    Moderate to severe hidradenitis suppurativa
    ConditionModerate to severe hidradenitis suppurativa
    Required classificationHurley stage II or III
    Coverage criterionDiagnosis must be moderate to severe hidradenitis suppurativa classified as Hurley stage II or III
    Covered non-infectious uveitis
    ConditionNon-infectious uveitis
    Required classificationOne of the following classifications
    Covered classificationsIntermediate, posterior, or panuveitis

    Initial Authorization

    Initial authorization

    Initial authorization may be granted through the new-plan member pathway or the applicable diagnosis-specific criteria.

    Initial authorization pathway

    • New-plan member pathway: Member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving the requested drug.Coverage effective date ≤90 days

      Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.

    • Diagnosis-specific pathway: Member meets all criteria for the applicable diagnosis.

      See the applicable diagnosis-specific criteria.

    ],

    Reauthorization

    Reauthorization

    Requests for reauthorization for all diagnoses will be approved when the following criterion is met.

    Continuation criterion: Submission of medical records, such as chart notes, documenting improvement in the member's condition, as evidenced by low disease activity or improvement in signs and symptoms of the condition.Documented improvement

    Applies to all covered diagnoses.

    Adalimumab Quantity Limits

    Adalimumab products
    ProductAdalimumab products
    Starter pack limit1 pack
    Limit periodPer 365 days
    Adalimumab products
    ProductAdalimumab products
    Dosage10 mg injection
    Quantity limit2 injections per 28 days

    Specialty Pharmacy Requirement

    Billing Rule

    Dispense through a contracted specialty pharmacy

    The specialty medication must be filled at a contracted specialty pharmacy.

    Preferred Adalimumab Products

    Billing Rule

    Preferred product: adalimumab-aaty

    Adalimumab-aaty is a preferred adalimumab product.

    Billing Rule

    Preferred product: adalimumab-adaz

    Adalimumab-adaz is a preferred adalimumab product.

    Billing Rule

    Preferred product: Hadlima

    Hadlima is a preferred adalimumab product.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyAdalimumab Products
    Policy CodePolicy N/A
    Change TypeFormulary update
    Effective DateJanuary 1, 2027
    Last ReviewSep 9, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through the Commercial/Exchange pharmacy benefit and use a contracted specialty pharmacy.
    SourceLink
    On This Page
    Diagnosis-Specific Coverage CriteriaCoverage and Quantity Coding DetailsAuthorization, Documentation, and Denial RisksClinical BackgroundCondition DefinitionsInitial AuthorizationReauthorizationAdalimumab Quantity LimitsSpecialty Pharmacy RequirementPreferred Adalimumab Products
    First-line biologic or targeted therapy: Severe psoriasis warrants a biologic DMARD or targeted synthetic therapy as first-line therapy.
    10 mg injection quantity
    Dosage10 mg injection
    Quantity limit2 injections
    Limit periodPer 28 days
    20 mg injection quantity
    Dosage20 mg injection
    Quantity limit4 injections
    Limit periodPer 28 days
    40 mg injection quantity
    Dosage40 mg injection
    Quantity limit4 injections
    Limit periodPer 28 days
    80 mg injection quantity
    Dosage80 mg injection
    Quantity limit2 injections
    Limit periodPer 28 days
    Documentation Required

    New-Plan Member Treatment Records

    For members new to the plan, submit medical records documenting that the member is currently receiving the requested drug.

    • Applies when the coverage effective date is less than or equal to 90 days.
    • Do not use samples or manufacturer patient assistance program supply as evidence of current treatment.
    Denial Risk

    Nonpreferred Product

    The plan's preferred adalimumab products are adalimumab-aaty, adalimumab-adaz, and Hadlima. All other adalimumab products are nonformulary and require applicable formulary authorization before coverage.

    • Preferred products: adalimumab-aaty, adalimumab-adaz, and Hadlima.
    • Nonpreferred or nonformulary adalimumab products may not be covered without the plan's required authorization.
    Denial Risk

    Diagnosis-Specific Criteria Not Met

    Coverage may be denied when the requested indication or required prerequisite therapy criteria are not documented.

    • Rheumatoid arthritis: document moderately to severely active RA and a minimum 3-month trial and failure, contraindication, or intolerance to one of methotrexate, leflunomide, or sulfasalazine at maximally tolerated doses.
    • Polyarticular juvenile idiopathic arthritis: document moderately to severely active pJIA and a minimum 6-week trial and failure, contraindication, or intolerance to one of leflunomide or methotrexate at maximally tolerated doses.
    • Ankylosing spondylitis: document active AS and a minimum 1-month trial and failure, contraindication, or intolerance to two different NSAIDs at maximally tolerated doses.
    • Plaque psoriasis: document moderate to severe chronic plaque psoriasis, at least 3% BSA or crucial-area involvement, and either the required topical-therapy trial or severe psoriasis warranting biologic DMARD or targeted synthetic therapy as first-line treatment.
    Documentation Required

    Continuation Medical Records

    For reauthorization of any covered diagnosis, submit chart notes or other medical records documenting improvement in the member's condition.

    • Documentation must show low disease activity or improvement in signs and symptoms.
    Denial Risk

    Insufficient Continuation Documentation

    Reauthorization may be denied when submitted records do not demonstrate improvement or disease control.

    • Ensure chart notes support low disease activity or improvement in signs and symptoms of the condition.
    Denial Risk

    Quantity Limit Exceeded

    Requests exceeding the applicable quantity limit may be denied.

    • Starter packs: 1 pack per 365 days.
    • 10 mg injection: 2 injections per 28 days.
    • 20 mg injection: 4 injections per 28 days.
    • 40 mg injection: 4 injections per 28 days.
    • 80 mg injection: 2 injections per 28 days.
    ref_placeholder_for_schema_fix
    Adalimumab products
    ProductAdalimumab products
    Dosage20 mg injection
    Quantity limit4 injections per 28 days
    Adalimumab products
    ProductAdalimumab products
    Dosage40 mg injection
    Quantity limit4 injections per 28 days
    Adalimumab products
    ProductAdalimumab products
    Dosage80 mg injection
    Quantity limit2 injections per 28 days